$HIMS · Hims & Hers Health, Inc.
Hims & Hers expanded its board from nine to ten directors and appointed Dr. Andrew Huberman, 51, effective November 4, 2026, to serve until the 2027 annual meeting. Huberman is not independent under NYSE standards and will not join any board committee. Separately, Hims entered a two-year advisory agreement paying Huberman $3.5M annually (plus up to $1M for short-form videos) and a three-year podcast marketing agreement with Scicomm Media LLC paying $5M annually, of which Huberman's interest is about $2.1M per year.
- Board expanded from nine to ten directors with Huberman's appointment effective November 4, 2026.
- Huberman does not meet NYSE independence requirements and will not join any board committee.
- Advisory agreement pays $3.5M cash annually for two years, plus up to $1M for short-form videos.
- Scicomm Media podcast marketing deal pays $5M annually for up to three years.
- Huberman's annual interest in the marketing agreement is approximately $2.1M.
Extended-hours trading shows HIMS at $22.38, down 2.44% from the $22.94 regular close, though the stock was already down 11.77% on the day before this filing.
A high-profile science influencer joins the board while the company commits up to $9.5M annually in related-party marketing spend.
_Not applicable._
Huberman is not independent under NYSE standards, and the marketing agreement can be terminated for convenience after November 5, 2027.